Join the club for FREE to access the whole archive and other member benefits.

UK's approval of casgevy paves the way for gene-edited treatment of blood disorders

Casgevy offers hope for patients with sickle cell disease and beta thalassemia

16-Nov-2023

Key points from article :

UK regulators have approved a gene therapy called Casgevy to treat sickle cell disease and beta thalassemia.

Casgevy is the first drug to be MHRA-licensed using the gene-editing tool CRISPR.

CRISPR allows for the precise manipulation of DNA to correct genetic defects.

Casgevy involves removing bone marrow stem cells from a patient and using CRISPR to edit the cells' DNA.

The modified cells are then infused back into the patient, allowing them to produce healthy hemoglobin.

In trials, Casgevy was found to be effective in treating both sickle cell disease and beta thalassemia.

The drug is personalized for each patient, which makes it expensive and time-consuming to produce.

The price of Casgevy has not yet been set, but it is likely to be high.

Mentioned in this article:

Click on resource name for more details.

Medicines and Healthcare products Regulatory Agency (MHRA)

Regulates medicines, medical devices and blood components for transfusion in the UK

Topics mentioned on this page:
Gene Therapy
UK's approval of casgevy paves the way for gene-edited treatment of blood disorders